+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
EV-Based Liquid Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F- Product Image
EV-Based Liquid Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F- Product Image
New

EV-Based Liquid Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • PDF Icon

    Report

  • 185 Pages
  • November 2025
  • Region: Global
  • TechSci Research
  • ID: 5956470
Free Webex Call
10% Free customization
Description Jump to:

Kits & Assays is the fastest growing segment, North America is the largest regional market

Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

 10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The Global EV-Based Liquid Biopsy Market, valued at USD 91.12 Million in 2024, is projected to experience a CAGR of 9.74% to reach USD 159.14 Million by 2030. Extracellular vesicle (EV)-based liquid biopsy involves the non-invasive analysis of disease-specific biomarkers encapsulated within extracellular vesicles, such as exosomes, circulating in bodily fluids like blood or urine.

These vesicles carry molecular cargoes including proteins, nucleic acids, and lipids, providing insights into the physiological and pathological state of originating cells. The market's expansion is significantly driven by the increasing global burden of chronic diseases, particularly cancer, and the rising demand for early, non-invasive diagnostic solutions. The inherent stability and abundance of EVs in biofluids, offering advantages over other circulating biomarkers, also act as key growth facilitators.

Key Market Drivers

The escalating global cancer burden fundamentally drives the EV-based liquid biopsy market. Traditional diagnostic methods often face limitations in early detection and continuous monitoring, areas where the non-invasive nature of EV liquid biopsies offers significant advantages. As cancer incidence continues its upward trajectory, the urgency for advanced, accessible diagnostic tools intensifies. According to the International Agency for Research on Cancer (IARC), in 2022, there were close to 20 million new cases of cancer worldwide. This pervasive health crisis necessitates innovative solutions that can accurately identify malignancies at earlier stages and monitor treatment efficacy without the invasiveness of tissue biopsies, directly propelling the adoption and development of EV-based platforms.

Key Market Challenges

A substantial challenge impeding the growth of the Global EV-Based Liquid Biopsy Market is the ongoing technical complexity associated with isolating and comprehensively characterizing extracellular vesicles (EVs) from complex biofluids. This inherent variability in isolation methods and subsequent characterization protocols often leads to significant issues with reproducibility and consistent clinical validation. The lack of standardized procedures across different laboratories and platforms directly compromises the reliability of test results, creating skepticism among clinicians and delaying the widespread adoption of EV-based diagnostic solutions.

Key Market Trends

The emergence of novel EV biomarkers is significantly shaping the global EV-based liquid biopsy market by enhancing diagnostic precision and expanding application areas. Research into disease-specific cargo within extracellular vesicles, such as proteins and nucleic acids, is uncovering new targets for early detection and disease monitoring across various pathologies. This focus on biomarker discovery drives the development of more sensitive and specific diagnostic assays.

According to the International Society for Extracellular Vesicles, its MISEV2023 guidelines, published in March 2024, garnered consensus from approximately 97% of surveyed members, reflecting a widespread scientific commitment to standardizing and advancing EV research which underpins biomarker identification. This collective effort is crucial for translating promising biomarker candidates into validated clinical tools. Furthermore, a review article in *Biology (Basel)* in September 2024, highlighted the therapeutic opportunity of tumor-derived extracellular vesicles, emphasizing their capacity to harbor cancer-derived cargo reflective of their cell-of-origin and their superior stability in blood for diagnostic and prognostic insights.

Key Market Players Profiled:

  • Horiba Ltd.
  • Thermo Fisher Scientific, Inc.
  • Lonza Group AG
  • Takara Bio Inc.
  • Abcam plc
  • Qiagen N.V.
  • Malvern Panalytical Ltd.
  • Revvity, Inc. (PerkinElmer, Inc)
  • Norgen Biotek Corp.
  • Bio-Techne Corporation

Report Scope:

In this report, the Global EV-Based Liquid Biopsy Market has been segmented into the following categories:

By Offering:

  • Kits & Assays
  • Services
  • Instruments

By Workflow:

  • Sample Preparation
  • Sequencing
  • Data Analysis

By Technology:

  • Isolation Technologies
  • Analysis Technologies

By Sample Type:

  • Blood
  • Urine
  • Saliva
  • Others

By End User:

  • Academic and Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Clinical Laboratories

By Region:

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global EV-Based Liquid Biopsy Market .

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global EV-Based Liquid Biopsy Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Offering (Kits & Assays, Services, Instruments)
5.2.2. By Workflow (Sample Preparation, Sequencing, Data Analysis)
5.2.3. By Technology (Isolation Technologies, Analysis Technologies)
5.2.4. By Sample Type (Blood, Urine, Saliva, Others)
5.2.5. By End User (Academic and Research Institutes, Pharmaceutical & Biotechnology Companies, Clinical Laboratories)
5.2.6. By Region
5.2.7. By Company (2024)
5.3. Market Map
6. North America EV-Based Liquid Biopsy Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Offering
6.2.2. By Workflow
6.2.3. By Technology
6.2.4. By Sample Type
6.2.5. By End User
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States EV-Based Liquid Biopsy Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Offering
6.3.1.2.2. By Workflow
6.3.1.2.3. By Technology
6.3.1.2.4. By Sample Type
6.3.1.2.5. By End User
6.3.2. Canada EV-Based Liquid Biopsy Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Offering
6.3.2.2.2. By Workflow
6.3.2.2.3. By Technology
6.3.2.2.4. By Sample Type
6.3.2.2.5. By End User
6.3.3. Mexico EV-Based Liquid Biopsy Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Offering
6.3.3.2.2. By Workflow
6.3.3.2.3. By Technology
6.3.3.2.4. By Sample Type
6.3.3.2.5. By End User
7. Europe EV-Based Liquid Biopsy Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Offering
7.2.2. By Workflow
7.2.3. By Technology
7.2.4. By Sample Type
7.2.5. By End User
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany EV-Based Liquid Biopsy Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Offering
7.3.1.2.2. By Workflow
7.3.1.2.3. By Technology
7.3.1.2.4. By Sample Type
7.3.1.2.5. By End User
7.3.2. France EV-Based Liquid Biopsy Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Offering
7.3.2.2.2. By Workflow
7.3.2.2.3. By Technology
7.3.2.2.4. By Sample Type
7.3.2.2.5. By End User
7.3.3. United Kingdom EV-Based Liquid Biopsy Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Offering
7.3.3.2.2. By Workflow
7.3.3.2.3. By Technology
7.3.3.2.4. By Sample Type
7.3.3.2.5. By End User
7.3.4. Italy EV-Based Liquid Biopsy Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Offering
7.3.4.2.2. By Workflow
7.3.4.2.3. By Technology
7.3.4.2.4. By Sample Type
7.3.4.2.5. By End User
7.3.5. Spain EV-Based Liquid Biopsy Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Offering
7.3.5.2.2. By Workflow
7.3.5.2.3. By Technology
7.3.5.2.4. By Sample Type
7.3.5.2.5. By End User
8. Asia-Pacific EV-Based Liquid Biopsy Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Offering
8.2.2. By Workflow
8.2.3. By Technology
8.2.4. By Sample Type
8.2.5. By End User
8.2.6. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China EV-Based Liquid Biopsy Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Offering
8.3.1.2.2. By Workflow
8.3.1.2.3. By Technology
8.3.1.2.4. By Sample Type
8.3.1.2.5. By End User
8.3.2. India EV-Based Liquid Biopsy Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Offering
8.3.2.2.2. By Workflow
8.3.2.2.3. By Technology
8.3.2.2.4. By Sample Type
8.3.2.2.5. By End User
8.3.3. Japan EV-Based Liquid Biopsy Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Offering
8.3.3.2.2. By Workflow
8.3.3.2.3. By Technology
8.3.3.2.4. By Sample Type
8.3.3.2.5. By End User
8.3.4. South Korea EV-Based Liquid Biopsy Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Offering
8.3.4.2.2. By Workflow
8.3.4.2.3. By Technology
8.3.4.2.4. By Sample Type
8.3.4.2.5. By End User
8.3.5. Australia EV-Based Liquid Biopsy Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Offering
8.3.5.2.2. By Workflow
8.3.5.2.3. By Technology
8.3.5.2.4. By Sample Type
8.3.5.2.5. By End User
9. Middle East & Africa EV-Based Liquid Biopsy Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Offering
9.2.2. By Workflow
9.2.3. By Technology
9.2.4. By Sample Type
9.2.5. By End User
9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia EV-Based Liquid Biopsy Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Offering
9.3.1.2.2. By Workflow
9.3.1.2.3. By Technology
9.3.1.2.4. By Sample Type
9.3.1.2.5. By End User
9.3.2. UAE EV-Based Liquid Biopsy Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Offering
9.3.2.2.2. By Workflow
9.3.2.2.3. By Technology
9.3.2.2.4. By Sample Type
9.3.2.2.5. By End User
9.3.3. South Africa EV-Based Liquid Biopsy Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Offering
9.3.3.2.2. By Workflow
9.3.3.2.3. By Technology
9.3.3.2.4. By Sample Type
9.3.3.2.5. By End User
10. South America EV-Based Liquid Biopsy Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Offering
10.2.2. By Workflow
10.2.3. By Technology
10.2.4. By Sample Type
10.2.5. By End User
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil EV-Based Liquid Biopsy Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Offering
10.3.1.2.2. By Workflow
10.3.1.2.3. By Technology
10.3.1.2.4. By Sample Type
10.3.1.2.5. By End User
10.3.2. Colombia EV-Based Liquid Biopsy Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Offering
10.3.2.2.2. By Workflow
10.3.2.2.3. By Technology
10.3.2.2.4. By Sample Type
10.3.2.2.5. By End User
10.3.3. Argentina EV-Based Liquid Biopsy Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Offering
10.3.3.2.2. By Workflow
10.3.3.2.3. By Technology
10.3.3.2.4. By Sample Type
10.3.3.2.5. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global EV-Based Liquid Biopsy Market : SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Horiba Ltd.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Thermo Fisher Scientific, Inc.
15.3. Lonza Group AG
15.4. Takara Bio Inc.
15.5. Abcam plc
15.6. Qiagen N.V.
15.7. Malvern Panalytical Ltd.
15.8. Revvity, Inc. (PerkinElmer, Inc)
15.9. Norgen Biotek Corp.
15.10. Bio-Techne Corporation
16. Strategic Recommendations17. About the Publisher & Disclaimer

Companies Mentioned

The companies profiled in this EV-Based Liquid Biopsy market report include:
  • Horiba Ltd.
  • Thermo Fisher Scientific, Inc.
  • Lonza Group AG
  • Takara Bio Inc.
  • Abcam plc
  • Qiagen N.V.
  • Malvern Panalytical Ltd.
  • Revvity, Inc. (PerkinElmer, Inc)
  • Norgen Biotek Corp.
  • Bio-Techne Corporation

Table Information

Report AttributeDetails
No. of Pages185
PublishedNovember 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 91.12 Million
Forecasted Market Value ( USD ) by 2030 $ 159.14 Million
Compound Annual Growth Rate9.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

EV-Based Liquid Biopsy Market - Global Forecast 2025-2032 - Product Image

EV-Based Liquid Biopsy Market - Global Forecast 2025-2032

  • Report
  • 186 Pages
  • Global
From
Liquid Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Liquid Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Breast Cancer Liquid Biopsy Global Market Report 2025 - Product Image

Breast Cancer Liquid Biopsy Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Liquid Biopsy Market - Global Forecast 2025-2032 - Product Image

Liquid Biopsy Market - Global Forecast 2025-2032

  • Report
  • 182 Pages
  • Global
From
Liquid Biopsy Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Liquid Biopsy Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 89 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.